Slide Show: Lung Cancer Highlights From ASCO 2014

June 20, 2014
Cancer Network Editors

This slide show highlights some of the top studies and news on lung cancer to come out of the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago.

References:

1. Roth JA, Sullivan SD, Ravelo A, et al. Low-dose computed tomography lung cancer screening in the Medicare program: Projected clinical, resource, and budget impact. Presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting; Abstract 6501. Read More.

2. Perol M, Ciuleanu TE, Arrieta O, et al. REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line treatment of stage IV non-small cell lung cancer (NSCLC) following disease progression after one prior platinum-based therapy. Presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting; Abstract LBA8006. Read More.

3. Janne PA, Ramalingam SS, Yang JCH, et al. Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor–resistant non-small cell lung cancer (NSCLC). Presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting; Abstract 8009. Read More.

4. Thatcher N, Hirsch FR, Szczesna A, et al. A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC). Presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting; Abstract 8008. Read More.

5. Kato T, Seto T, Nishio M, et al. Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation–positive nonsquamous non-small cell lung cancer (NSCLC): An open-label randomized trial. Presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting; Abstract 8005. Read More.

Joshua A. Roth, PhD, MHA, discusses a new study (abstract 6501) that found that implementation of a national lung cancer screening program using low-dose CT will identify almost 55,000 additional lung cancer cases over 5 years, but will add $9.3 billion to Medicare expenditures. Photo by © ASCO/Rodney White 2014.[1]

Maurice Perol, MD, discusses results of the REVEL trial, which found that the addition of ramucirumab to docetaxel improved outcomes over placebo with docetaxel as a second-line treatment for patients with advanced non-small-cell lung cancer. Photo by © ASCO/Scott Morgan 2014.[2]

Pasi A. Jänne, MD, PhD, discusses results of a phase I dose-escalation trial where a novel agent known as AZD9291 showed promising results among non-small-cell lung cancer patients whose disease progressed after treatment with EGFR-targeting tyrosine kinase inhibitors. Photo by © ASCO/Silas Crews 2014.[3]

The addition of the anti-EGFR antibody necitumumab to gemcitabine-cisplatin chemotherapy resulted in a modest but significant benefit to patients with stage IV squamous cell non-small-cell lung cancer, according to results of the SQUIRE study (abstract 8008).[4]

In a new phase II study (abstract 8005), the addition of bevacizumab to erlotinib as first-line therapy yielded a significantly extended progression-free survival in patients with advanced EGFR-mutation-positive non-small-cell lung cancer. Image source: Roche.[5]

PreviousNext

Related Content:

ASCO Lung Cancer | Conference